The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease by unknown
RESEARCH Open Access
The CXCR4-CXCL12 axis in Ewing sarcoma:
promotion of tumor growth rather than
metastatic disease
Dagmar Berghuis1,2, Marco W Schilham2, Susy J Santos2, Suvi Savola3, Helen J Knowles4, Uta Dirksen5,
Karl-Ludwig Schaefer6, Jukka Vakkila3, Pancras CW Hogendoorn1 and Arjan C Lankester2*
Abstract
Background: Chemokine receptor CXCR4, together with its ligand CXCL12, plays critical roles in cancer progression,
including growth, metastasis and angiogenesis. Ewing sarcoma is a sarcoma with poor prognosis despite current
therapies, particularly for patients with advanced-stage disease. Lungs and bone (marrow), organs of predilection
for (primary/metastatic) Ewing sarcoma, represent predominant CXCL12 sources.
Methods: To gain insight into the role of the CXCR4-CXCL12 axis in Ewing sarcoma, CXCR4, CXCL12 and
hypoxia-inducible factor-1α protein expression was studied in therapy-naïve and metastatic tumors by
immunohistochemistry. CXCR4 function was assessed in vitro, by flow cytometry and proliferation/ cell viability
assays, in the presence of recombinant CXCL12 and/or CXCR4-antagonist AMD3100 or under hypoxic conditions.
Results: Whereas CXCR4 was predominantly expressed by tumor cells, CXCL12 was observed in both tumor and
stromal areas. Survival analysis revealed an (expression level-dependent) negative impact of CXCR4 expression
(p < 0.04). A role for the CXCR4-CXCL12 axis in Ewing sarcoma growth was suggested by our observations that
i) CXCR4 expression correlated positively with tumor volume at diagnosis (p = 0.013), ii) CXCL12 was present within
the microenvironment of virtually all cases, iii) CXCL12 induced proliferation of CXCR4-positive Ewing sarcoma cell
lines, which could be abrogated by AMD3100. CXCR4 expression was not correlated with occurrence of metastatic
disease. Also, therapy-naïve tumors demonstrated higher CXCR4 expression as compared to metastases (p = 0.027).
Evaluation of in vivo hypoxia-inducible factor-1α expression and culture of cells under hypoxic conditions revealed
no role for hypoxia in CXCR4 expression.
Conclusions: Together, our results imply a crucial role for the CXCR4-CXCL12 axis in auto- and/or paracrine growth
stimulation. Integration of CXCR4-targeting strategies into first- and/or second-line treatment regimens may
represent a promising treatment option for Ewing sarcoma.
Keywords: Ewing sarcoma, CXCR4, CXCL12 (stromal-cell derived factor-1 (SDF-1)), Chemokine, Growth signaling,
Hypoxia, Metastasis, Prognosis, Therapy
* Correspondence: a.lankester@lumc.nl
2Department of Pediatrics, Leiden University Medical Center, Albinusdreef 2,
2300, RC Leiden, the Netherlands
Full list of author information is available at the end of the article
CLINICAL SARCOMA RESEARCH
© 2012 Berghuis et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Berghuis et al. Clinical Sarcoma Research 2012, 2:24
http://www.clinicalsarcomaresearch.com/content/2/1/24
Background
The chemokine network, initially described as an essen-
tial mediator of directional cell migration in inflamma-
tion and immune cell homing, has become increasingly
recognized as contributing to a broad spectrum of other
physiological and pathological processes, including can-
cer [1]. Although cancers of different histological origin
express different chemokine receptors and/or (corre-
sponding) ligands, chemokine receptor CXCR4 together
with its cognate ligand CXCL12 (stromal cell-derived
factor-1/SDF-1) is the most widely expressed (as
reviewed by [2]). Constitutive CXCR4 expression has
been detected in a range of adult tissues, including
hematopoietic cells, vascular smooth muscle and endo-
thelial cells and epithelial cells of different origin,
whereas CXCL12 is constitutively expressed by stromal
cells within the lungs and bone marrow microenviron-
ment [2]. Hypoxia-inducible factor-1α (HIF-1α), a well-
characterized inducer of gene transcription in hypoxic
cells, induces expression of both CXCL12 and CXCR4
in ischemic areas [3,4]. Physiologically, the CXCR4-
CXCL12 axis has important roles in hematopoiesis, de-
velopment and organization of the immune system and
(ischemic) tissue repair and regeneration. In cancer, this
axis has been reported to play critical roles in tumor
progression, including promotion of tumor cell prolif-
eration and survival [5], metastatic processes [6] and
angiogenesis [7]. Currently, after having demonstrated
anti-tumor activity in pre-clinical and animal tumor
models [8], several CXCR4 antagonists are being evalu-
ated in clinical studies for treatment of patients with
hematological and solid tumors [9].
Ewing sarcoma (EWS) is an aggressive round cell sar-
coma affecting bone or, rarely, soft tissue in predomin-
antly children and young adults [10]. This tumor is
characterized by specific gene fusions most commonly
containing TET gene family products, and rarely other
activating transcription factors [11,12]. Despite current
multimodal therapies, survival of patients has not
improved significantly during the past decade. Patients
with refractory and/or (primary) metastatic disease have
the most unfavorable prognosis, which has recently been
demonstrated to be independent of gene fusion type
[13,14]. Organs of predilection for EWS metastases are
lungs and bone (marrow), which represent rich sources
of CXCL12. Recently, high CXCR4 gene expression was
reported to associate with metastatic phenotype in EWS
[15]. Moreover, CXCL12 has been demonstrated to con-
tribute to neovascularization and EWS tumor growth in
a mouse xenograft model [16]. As yet, no information
exists on CXCR4/CXCL12 protein expression and their
(functional) consequences in EWS.
To gain insight into the role of the CXCR4-CXCL12
axis in EWS biology, CXCR4 expression and
functionality (in the presence of CXCL12 and/or
CXCR4-antagonist AMD3100) were evaluated in a
large panel of therapy-naïve and metastatic tumors and
cell lines, respectively. We demonstrate an expression
level-dependent negative impact of CXCR4 protein ex-
pression on patients’ overall survival and point to a
crucial role for auto- and/or paracrine growth signaling
via the CXCR4-CXCL12 axis.
Methods
Ewing sarcoma patients and samples
Formalin-fixed, paraffin-embedded therapy-naïve (n =
44) as well as (sequential) metastatic (n = 16) EWS sam-
ples from 47 different patients were retrieved from the
Department of Pathology, LUMC and a tissue array con-
taining 2mm-diameter tissue-cores (Institute of Path-
ology, Heinrich-Heine University, Dusseldorf, Germany).
Histology and tumor content were verified by a specia-
lized bone pathologist (PCWH). Diagnosis was estab-
lished according to WHO criteria, including standard
confirmatory immunohistochemistry and fusion tran-
script type. For patients with clinical information avail-
able (Additional file 1: Table S1), mean age at diagnosis
was 19 years (range 1–43 years). Follow-up (mean/
median duration of follow-up: 60/44 months, respect-
ively) provided information concerning (initial) disease
extension, chemotherapy response, recurrence rate and
performance state. All patient material was coded, such
that code breaking and correlation with clinical data
were only possible for physicians involved in treatment
of the patients. Subsequent research was conducted fol-
lowing the ethical guidelines of the national organization
of scientific societies (FEDERA).
Ewing sarcoma cell lines
EWS cell lines EW3, RD-ES, SK-ES-1, SK-N-MC,
CADO-ES and STA-ET2.1 [17] and breast cancer cell
line MCF-7 (ATCC, Rockville, MD) were cultured in
RPMI-1640 supplemented with streptomycin/ penicillin
(Invitrogen, Paisley, United Kingdom) and 10% fetal
bovine serum ((FBS); Greiner Bio-One, Alphen a/d
Rijn, The Netherlands). TC71 [17] and IOR/BER
(kindly provided by dr. K. Scotlandi, Instituto Orthope-
dico Rizzoli, Bologna, Italy) were cultured in Iscove’s
Modified Dulbecco’s Medium supplemented with
streptomycin/ penicillin and 10% FBS. For proliferation
assays, cells (at densities ranging from 3-15x103 cells/
well in 96-well-plates) were cultured for seven days in
serum-free medium in the absence or presence of
100ng/ml CXCL12, 1000ng/ml AMD3100 or both.
Afterwards, cell viability was measured by 3-(4,5 -
dimethyl-thiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability
assay (Promega Benelux, Leiden, The Netherlands), a
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colorimetric method for determining the number of vi-
able cells in proliferation assays. The MTS tetrazolium
compound is bioreduced by cells into a colored product
that is soluble in tissue culture medium. The quantity of
colored product as measured by the absorbance at
490nm is directly proportional to the number of living
cells in culture. Submission of cells to 24-hours of hyp-
oxia was performed in 0.1% O2, 5% CO2, balance N2 in
a MiniGalaxy incubator (RS Biotech, Irvine, UK). The
effectiveness of this approach for induction of hypoxia/
HIF-1α expression has recently been demonstrated [18].
Cell lines were routinely screened for mycoplasma con-
tamination. Periodical authentication was performed by
Short Tandem Repeat profiling and molecular HLA
typing.
Antibodies and reagents
The antibodies used for staining of antigens by immuno-
histochemistry and flow cytometry are described in Add-
itional file 2: Table S2. Recombinant human CXCL12
was obtained from R&D Systems (cat.no. 350-NS/CF;
Abingdon, UK). AMD3100 (octahydrochloride hydrate)
was purchased from Sigma-Aldrich (A5602; Zwijn-
drecht, Netherlands).
Flow cytometric analysis of CXCR4 surface expression
Flow cytometric analysis was performed on a FACScali-
bur (Beckton Dickinson, Franklin Lakes, NJ) and results
were analyzed using Cellquest software. In short, cells
were collected, centrifuged, washed in 1% BSA/ PBS,
stained with primary anti-CXCR4 antibody and, subse-
quently, stained with a fluorochrome-labelled secondary
antibody. Ligand expression was represented as fold in-
crease in Mean Fluorescence Intensity (MFI) over iso-
type control staining (MFI-ratio).
Immunohistochemistry for detection of CXCR4, CXCL12
and HIF-1 expression in Ewing sarcoma tumor samples
4μm sections containing representative tumor, as verified
by a specialized bone pathologist (PCWH), were depar-
affinized and citrate antigen retrieval was performed.
Subsequent immunohistochemical stainings were per-
formed and (semi-quantitatively) scored according to the
quality control system as proposed by Ruiter et al.: the
intensity of staining was scored as 0, 1, 2 or 3 indicating
absent, weak, moderate or strong expression, respect-
ively. Percentages of positive cells were scored as 0 for
0%, 1 for 1–5%, 2 for 5–25%, 3 for 25–50%, 4 for 50–
75%, and 5 for 75–100%. The sum of both scores was
used to identify four categories of expression: absent (0–
2), weak (3–4), moderate (5–6), strong/ homogeneous
(7–8) [18,19]. (Decalcified) tonsil tissue sections were
used as positive control slides during initial optimiza-
tion of immunohistochemical staining procedures. A
decalcification procedure (formic acid) was applied to
determine its influence on the immunoreactivity of
epitopes. Quality of samples was guaranteed by (previ-
ous) immunohistochemical staining for CD99.
Statistical analyses
Statistical analyses were performed with SPSS version
16.0 software package. Survival analyses were per-
formed according to Kaplan Meier and differences in
survival curves were assessed with the log-rank test.
Pearson correlation analysis was used for assessment
of associations between expression levels within indi-
vidual samples. T-tests or repeated measures ANOVA
with Bonferroni’s multiple comparison post hoc tests
were used for comparison of expression levels between
samples and associations between expression levels and
clinicopathological parameters. P < 0.05 was considered
statistically significant.
Results
CXCR4 expression in Ewing sarcoma: negative impact on
survival
A panel of therapy-naïve (n = 44) and metastatic (n = 16)
EWS samples were evaluated by immunohistochemistry
for CXCR4 and CXCL12 expression. Variation between
as well as within individual samples was observed, ran-
ging from complete lack of expression of CXCR4 and
CXCL12 to homogeneous expression of these proteins
(Table 1; Figure 1A-F). Immunoreactivity for both
CXCR4 and CXCL12 was exclusively localized in the
cytoplasm of cells. Whereas CXCR4 was solely expressed
by tumor cells, CXCL12 was observed in both tumor
and stromal areas. As demonstrated in Table 1, CXCR4
expression was observed in 64% (28/44) of therapy-naïve
and 47% (7/15) of metastatic tumors. CXCL12 was de-
tectable in 65% (28/43) of therapy-naïve and 81% (13/
16) of metastatic lesions. Noteworthy, stromal CXCL12
expression was detectable in nearly all cases (in 95% (41/
43) of therapy-naïve cases and in all metastatic lesions),
regardless of CXCR4/ CXCL12 expression by tumor
cells. No correlation existed between CXCR4 and
CXCL12 expression levels within individual tumor sam-
ples (data not shown). Comparisons between sample
types, however, demonstrated significantly higher
CXCR4 expression levels in therapy-naïve as compared
to (sequential) metastatic EWS cases (t-test, p = 0.027)
(Table 1). Kaplan-Meier survival analysis revealed a
negative impact of CXCR4 expression in therapy-naïve
samples (n = 30) on patients’ overall survival (log-rank
test, p = 0.04) (Figure 2A). Extended analyses demon-
strated this impact to be expression level-dependent
(log-rank test, p = 0.017) (Figure 2B). No such effect was
observed for CXCL12 (data not shown). For cases with
clinical information available (n ≥ 25), analysis of the
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relationship with established prognostic factors in EWS
[13] showed a positive correlation between CXCR4 ex-
pression in therapy-naïve samples and tumor volume at
diagnosis (< or > 200 ml) (Pearson Chi-square, p =
0.013). No correlations were observed with tumor site,
disease extension, histologic response to chemotherapy
or relapsed metastatic disease (Additional file 1: Table
S1). Due to limited sample size, multivariate analysis to
assess CXCR4 expression as independent prognostic fac-
tor in Ewing sarcoma could not be performed.
A crucial role for the CXCR4-CXCL12 axis in promotion of
Ewing sarcoma growth
The observed correlation between CXCR4 expression
and tumor volume might either be a reflection of
decreased oxygen concentrations in larger/ fast-growing
tumors resulting in HIF-1α-induced CXCR4 expression,
or might be caused by increased tumor cell proliferation
via auto- and/or paracrine CXCL12/ CXCR4-mediated
growth signalling. To explore the first potential mechan-
ism, hypoxia-induced CXCR4 expression and the correl-
ation between CXCR4 and HIF-1α protein expression
levels were studied in EWS cell lines (n = 8) cultured
under suboptimal conditions and therapy-naïve tumors
(n = 38), respectively.
Whereas flow cytometric analysis revealed detectable
constitutive CXCR4 surface expression in all eight cell
lines evaluated, only four cell lines (CADO-ES, EW3,
IOR/BER, RD-ES) demonstrated substantial levels of ex-
pression of this protein (Mean Fluorescence Intensity-
ratio (over isotype control) >10), comparable to (positive
Table 1 Immunohistochemical expression analysis of the
CXCR4-CXCL12 axis in Ewing sarcoma




1 lung metastasis (3) - - +/−
bone metastasis (7) - - +/−
2 lung metastasis (2) - + +
3 therapy-naive biopsy +/− + +
lung metastasis (5,5) - - +/−
4 therapy-naive biopsy ++ +/− +
lung metastasis (3) - + ++
lung metastasis (4) - + ++
5 therapy-naive biopsy ++ +/− ++
bone metastasis (1) n.e. +/− +
6 therapy-naive biopsy + ++ n.e.
lung metastasis (1) +/− +/− +/−
7 therapy-naive biopsy ++ ++ +
8 therapy-naive biopsy ++ +/− +
bone metastasis (2,5) + ++ ++
9 therapy-naive biopsy - + +
lung metastasis (0,5) + + ++
10 therapy-naive biopsy + - +/−
11 therapy-naive biopsy - + +/−
12 therapy-naive biopsy + +/− +
13 therapy-naive biopsy ++ - +/−
14 therapy-naive biopsy - +/− +
15 therapy-naive biopsy - - +/−
16 therapy-naive biopsy - + +/−
17 therapy-naive biopsy - + +
18 therapy-naive biopsy + +/− +/−
19 therapy-naive biopsy - +/− +
20 therapy-naive biopsy +/− - +
21 therapy-naive biopsy - - +/−
22 therapy-naive biopsy - - -
23 therapy-naive biopsy - +/− +/−
24 therapy-naive biopsy +/− +/− +/−
25 therapy-naive biopsy ++ - -
26 therapy-naive biopsy - + +
27 therapy-naive biopsy + +/− +
28 therapy-naive biopsy ++ +/− +
29 therapy naive biopsy - - +/−
30 therapy-naive biopsy ++ ++ +
31 therapy-naive biopsy + - ++
32 therapy-naive biopsy + + +
33 therapy-naive biopsy - - +/−
34 therapy-naive biopsy ++ + +
35 therapy-naive biopsy + - +/−
36 therapy-naive biopsy + + +
37 therapy-naive biopsy + - +
Table 1 Immunohistochemical expression analysis of the
CXCR4-CXCL12 axis in Ewing sarcoma (Continued)
38 therapy-naive biopsy ++ n.e. n.e.
39 therapy-naive biopsy ++ - +/−
40 therapy-naive biopsy - - +/−
41 therapy-naive biopsy + + +
42 therapy-naive biopsy + - +/−
43 therapy-naive biopsy - ++ +
44 therapy-naive biopsy - + +
45 lung metastasis (1,5) +/− +/− ++
bone metastasis (2,5) ++ +/− +
lung metastasis (2,5) - + ++
lung metastasis (4) - +/− ++
lung metastasis (4) +/− +/− +
lung metastasis (5) + + +
46 therapy-naive biopsy + + +
47 therapy-naive biopsy +/− ++ ++
aUPN = unique patient number. n.e. = not evaluable; - = absent expression;
‘+/− = weak expression; + =moderate expression; ++ = strong expression.
bt-test: therapy-naive Ewing sarcoma demonstrated significantly higher CXCR4
expression levels as compared to metastatic lesions (p = 0.027).
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control) breast cancer cell line MCF-7 (Figure 3A).
Stabilization of HIF-1α protein in response to hypoxia
has previously been demonstrated in EWS cell lines
[18,20]. To evaluate the impact of hypoxia/ HIF-1α acti-
vation on CXCR4 expression in EWS, cell lines expres-
sing either substantial (CADO-ES, EW3, RD-ES) or
barely detectable (STA-ET2.1, TC71) levels of CXCR4
were subjected to 24-hours of hypoxia (0.1% O2). Cul-
ture under hypoxic conditions, compared to normoxia,
did not systematically affect CXCR4 surface expression
(despite successful induction of VEGF, as previously
described [18]) (Figure 3B). Consistent with these find-
ings, correlation analysis of in vivo HIF-1α [18] and
CXCR4 expression revealed lack of correlation between
expression levels of these proteins within individual
tumor samples (Figure 3C).
To assess the possible contribution of the CXCR4-
CXCL12 axis to EWS proliferation, cell lines were cul-
tured in serum-free medium in the absence or presence
of recombinant CXCL12. As demonstrated in Figure 3D,
stimulation with 100ng/ml CXCL12 for seven days sig-
nificantly increased cell numbers in cell lines expressing
substantial levels of constitutive CXCR4 (CADO-ES,
EW3, IOR/BER; repeated measures ANOVA with Bon-
ferroni’s multiple comparison post hoc test, p < 0.001),
whereas no effects were observed in cell lines with min-
imal levels of constitutive CXCR4 expression (SK-ES-1,
SK-N-MC, STA-ET2.1). Addition of CXCR4-antagonist
AMD3100 at 1μg/ml completely abrogated the CXCL12-
induced proliferation of EWS cell lines. AMD3100
treatment alone did not affect (spontaneous) cell prolif-
eration (Figure 3D).
Discussion
Expression of the CXCR4-CXCL12 axis has been
reported to coordinate events critical to tumor develop-
ment and/or progression in (solid) tumors of different
histological origin [2]. The present study demonstrates
an (expression level-dependent) negative prognostic
Figure 1 Immunohistochemical analysis of expression of the CXCR4-CXCL12 axis in Ewing sarcoma. A-F. Light micrographs (20x
magnification) of immunohistochemical stainings for CXCR4 and CXCL12 expression in therapy-naive and metastatic EWS. Representative
examples. A-C: strong (++), moderate (+) and absent (−) CXCR4 expression, respectively. D-F: strong (++), moderate (+) and weak (+/−) CXCL12
expression, respectively. Whereas CXCR4 was expressed solely by tumor cells, CXCL12 was observed in both tumor and stromal areas. Insets:
immunoreactivity for both CXCR4 and CXCL12 was exclusively localized in the cytoplasm of cells. Intensity of staining was (semi-quantitatively)
scored according to the quality control system as proposed by Ruiter et al. (see Methods section) [19]. (Decalcified) tonsil tissue sections were
used for initial optimization of immunohistochemical staining procedures.
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impact of CXCR4 protein expression in therapy-naïve
EWS and points to a role for the CXCR4-CXCL12 axis
in promotion of EWS cell growth. CXCL12-dependent
modulation of tumor cell proliferation and survival
(under suboptimal conditions) has been observed in sev-
eral tumor types, including ovarian carcinoma [21],
small cell lung cancer [22] and prostate cancer [23].
Here, we demonstrate positive correlations between
CXCR4 expression levels in therapy-naïve EWS and
tumor volume at diagnosis. Moreover, and consistent
with previous gene expression results [15,24], we show
expression of CXCL12 protein by most EWS tumors
(65%) and, explicitly, within the tumor microenviron-
ment of virtually all (>95%) EWS cases. Combined, these
observations may reflect the existence of auto- and/ or
paracrine growth stimulatory loops, mediated by the
CXCR4-CXCL12 axis. Indeed, in vitro functional ana-
lyses demonstrate CXCL12-induced proliferation of
EWS cell lines expressing substantial levels of CXCR4,
which could be inhibited by CXCR4-antagonist
AMD3100. Addition of AMD3100 alone did not inter-
fere with spontaneous cell proliferation, suggesting a
predominant role for paracrine (stroma-derived
CXCL12) rather than autocrine (tumor cell-derived
CXCL12 [24]) signalling. No correlations were observed
with other established prognostic factors in Ewing sar-
coma. Due to limited sample size, multivariate analysis
to assess CXCR4 expression as independent prognostic
factor in Ewing sarcoma could not be performed. More-
over, due to the nature of this (bone) tumor, attempts to
establish primary tumor cell cultures from therapy-naive
biopsies for evaluation of CXCL12-induced proliferation
have so far been unsuccessful. Nuclear localization of
CXCR4 has been described, and demonstrated to correl-
ate with disease progression, in several distinct cancer
types [25,26]. Within our series of therapy-naive and
metastatic Ewing sarcoma, however, no nuclear accumu-
lation of CXCR4 has been observed.
Recently, CXCR4 gene expression was reported to as-
sociate with both EWS and osteosarcoma metastases
[15,27]. Although we previously observed a correlation
between CXCR4 gene expression and disease extension/
metastatic disease at diagnosis (unpublished results), the
current study does not shown any correlation between
CXCR4 protein expression and occurrence of metastatic
disease. Moreover, metastatic EWS lesions demonstrated
significantly lower CXCR4 protein expression levels as
compared to (corresponding) therapy-naïve tumors.
Reduced expression of CXCR4 in metastatic lesions as
compared to corresponding primary tumors has been
reported in breast carcinoma, and hypothesized to be
due to CXCL12-induced internalization and degradation
and/or lower microenvironmental HIF-1α levels [28].
With regard to EWS, no significant differences in
CXCL12 protein expression levels (in neither tumor nor
stromal areas) were observed between therapy-naïve and
metastatic lesions (data not shown). Moreover, although
no data exist on HIF-1α expression in metastatic EWS
lesions, our in vitro and in vivo analyses revealed no ef-
fect of hypoxia on CXCR4 expression nor a correlation
between HIF-1α and CXCR4 expression levels
(Figure 3B and Figure 3C, respectively). An alternative
explanation for the observed reduced expression of
CXCR4 in metastatic as compared to therapy-naïve
EWS lesions might be that the CXCR4-CXCL12 axis is
essential for retention of EWS cells within the primary
tumor site, as has been described for CD34+
hematopoietic stem cells and leukemic cells within the
hematopoietic microenvironment [2] and, more recently,
for osteosarcoma [29]. Hypothetically, reduced expression
























































Figure 2 Negative impact of CXCR4 expression in therapy-naïve
Ewing sarcoma. Kaplan-Meier survival analysis. CXCR4 expression
level plotted according to the cut-off values as shown in Table 1:
CXCR4 negative (absent (−) expression), CXCR4 positive (weak (+/−),
moderate (+) or strong (++) expression). A. Inferior survival of
patients with CXCR4 positive therapy-naïve tumors compared to
patients with tumors lacking expression of this protein. B. Expression
level-dependent impact of CXCR4 expression on patients’ overall
survival. Inferior survival of patients with therapy-naïve tumors
demonstrating strong CXCR4 expression compared to patients with
weak-moderate or absent expression of this protein.
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of CXCR4 might result in preferential metastasizing of
individual cells, provided that alternative growth factors
are present. Whether the apparent discrepancy in correl-
ation of CXCR4 gene transcript ([15]) and CXCR4 pro-
tein expression (current study) with metastatic disease in
EWS reflects true biological differences (e.g. differences
at the mRNA level are not reflected at the protein level
(or vice versa), due to post-transcriptional and/or -trans-
lational regulation) or are attributable to technical differ-
ences (e.g. different samples and/or sensitivity and
dynamic ranges of the methods used for mRNA tran-
script and protein analysis) is not known. Based on our
results, we delineate a role for the CXCR4-CXCL12 axis
in promotion of EWS cell growth rather than its meta-
static potential.
Hypoxia is a common phenomenon in (large and/or
fast-growing) solid tumors, which is associated with
therapy-resistance and represents an independent prog-
nostic indicator of poor outcome. HIF-1α, being the best
characterized inducer of gene transcription in hypoxic
cells, is overexpressed in various cancer types includ-
ing EWS [18,20,30], and a key role for this protein in
hypoxic induction of CXCR4 has been described [3,31].
Although the observed positive correlation between
Figure 3 Expression and functionality of CXCR4 in Ewing sarcoma: role for CXCL12-dependent modulation of tumor cell proliferation.
A. Constitutive surface expression of CXCR4 in EWS cell lines, as assessed by flow cytometry. Results are expressed as the mean ± SD MFI-ratio,
obtained in at least two independent experiments. Breast cancer cell line MCF-7 was used as a positive control. B. Flow cytometric analysis of
24-hours hypoxia (0.1% O2)-induced CXCR4 expression in cell lines having either substantial (CADO-ES, EW3, RD-ES) or minimal (STA-ET2.1, TC71)
levels of constitutive CXCR4 expression. Results are expressed as the mean ± SD fold increase in MFI-ratio over normoxic control, obtained in at
least two independent experiments. Culture under hypoxic conditions (as previously described [18]) did not systematically affect CXCR4
expression. C. Pearson correlation analysis: lack of correlation between in vivo HIF-1α [18] and CXCR4 protein expression levels in 38 therapy-naïve
EWS. D. Stimulation of cell lines expressing substantial levels of CXCR4 (CADO-ES, EW3, IOR/BER) with 100ng/ml recombinant CXCL12 for seven
days significantly increased cell numbers. Addition of AMD3100 (1μg/ml) abrogated the increase in cell numbers. No effects were observed in cell
lines with minimal levels of CXCR4 expression (SK-ES-1, SK-N-MC, STA-ET2.1), nor did AMD3100 treatment alone affect cell proliferation. Cells were
cultured in serum-free medium. Cell viability was measured by MTS cell viability assay, a colorimetric method for determining the number of
viable cells in proliferation assays (see Methods section). Results are expressed as the mean ± SD fold increase in cell numbers over (untreated)
medium control, obtained in at least two independent experiments.
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CXCR4 expression in therapy-naïve EWS and tumor
volume at diagnosis might have been indicative for
hypoxia-induced HIF1α-dependent CXCR4 activation,
our analyses did not provide support for a contribution
of hypoxia to CXCR4 expression in this tumor. In
addition to the observed lack of correlation between
HIF-1α and CXCR4 protein expression within individual
tumor samples, culture of cell lines under hypoxic con-
ditions did not affect CXCR4 surface expression. These
observations are in line with results previously obtained
by Aryee et al., demonstrating a lack of change in
CXCR4 pathway genes upon hypoxic exposure [20].
Until rather recently, CXCR4 and CXCL12 were con-
sidered exclusive partners. However, a second CXCL12-
binding chemokine receptor, CXCR7, was identified and
demonstrated to be involved in progression of several
cancer types, including (pediatric) sarcomas [29,32,33].
In Ewing sarcoma, CXCR7 gene expression was recently
reported to associate with patient survival [15]. As yet,
no data exist on CXCR7 protein expression in Ewing
sarcoma. Our preliminary results point to limited ex-
pression of this chemokine receptor in Ewing sarcoma
cell lines (CXCR7 surface expression, as assessed by flow
cytometry, in 1/10 cell lines). In vivo studies, using
Ewing sarcoma samples or either murine or human
(xenografted) tumor models may provide further insight
into the role of the CXCR7-CXCR4-CXCL12 axis in
Ewing sarcoma.
Hitherto, our results indicate that the CXCR4/CXCL12
axis is frequently expressed in EWS and affects tumor
progression and patient survival by promoting cell
growth. Successful inhibition of EWS proliferation by
AMD3100, one of several CXCR4-specific antagonists
that are currently being evaluated for treatment of
patients with both hematological and solid tumors [9]
indicates that disruption of the CXCR4-CXCL12 axis
may indeed interfere with EWS progression. Integration
of strategies that target CXCR4 signaling into either
first- or second-line treatment regimens may represent a
promising treatment option for patients with EWS.
Conclusions
Patients with Ewing sarcoma (EWS) have a poor progno-
sis, despite current multimodal therapy. Integration of
targeted strategies into first-line treatment regimens or
introduction of these approaches as second-line therapy
may represent promising treatment options. Chemokine
receptor CXCR4, together with its ligand CXCL12, plays
critical roles in cancer progression, including growth,
metastasis and angiogenesis. Lungs and bone (marrow),
organs of predilection for (primary/ metastatic) EWS, rep-
resent predominant CXCL12 sources Currently, after hav-
ing demonstrated anti-tumor activity in pre-clinical and
animal tumor models, several CXCR4 antagonists are
being evaluated in clinical studies for treatment of
patients with hematological and solid tumors. Here, we
demonstrate an expression level-dependent negative im-
pact of CXCR4 protein expression on EWS patients’
overall survival and provide evidence for a crucial role
for the CXCR4-CXCL12 axis in promotion of EWS cell
growth. Successful inhibition of EWS proliferation by
CXCR4 antagonist AMD3100 indicates that disruption
of the CXCR4-CXCL12 axis may indeed interfere with
disease progression and provides a rationale for integ-
ration of CXCR4-targeting strategies in first- and/or
second-line treatment regimens for EWS.
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